Analyst consensus rating
Larimar Therapeutics Analyst Rating: none
Direct answer
Larimar Therapeutics's consensus rating is none.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.40.
Forecast evidence checked November 9, 2026.
Get free Larimar Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.47
- Average price target
- $14.40
- High price target
- $26.00
- Low price target
- $5.00
- Low target gap
- +102.8%
- Target upside
- +484.2%
- High target gap
- +954.8%
- Target range width
- 851.9%
- Consensus rating
- none
- Analysts
- 10
- Evidence date
- November 9, 2026
- Valid through
- November 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Larimar Therapeutics?
Larimar Therapeutics has a verified none consensus. The same dataset has an average price target of $14.40.
How far are Larimar Therapeutics's low and high targets from the recorded price?
The low target implies +102.8%, while the high target implies +954.8%.
How many analysts are included in Larimar Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Larimar Therapeutics's target upside or downside calculated?
The average target of $14.40 is divided by the recorded price of $2.47, then one is subtracted to produce +484.2%. This does not guarantee a future return.
When was Larimar Therapeutics's analyst forecast verified?
The data was verified on 2026-11-09. The dataset is valid through 2026-11-16.